OPIOIDS 2009 <454>

Database EMBASE

Accession Number 2009384629

Authors Raby W.N. Carpenter K.M. Rothenberg J. Brooks A.C. Jiang H. Sullivan M. Bisaga A. Comer S. Nunes E.V.

Institution

(Raby, Carpenter, Rothenberg, Brooks, Jiang, Sullivan, Bisaga, Comer, Nunes) Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY,

(Brooks) Treatment Research Institute, Philadelphia, PA,

(Raby) Division on Substance Abuse, Unit 66, New York State Psychiatric Institute, 1051 Riverside Dr, NewYork, NY 10032,

Country of Publication

United Kingdom

Title

Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Source

American Journal on Addictions. 18(4)(pp 301-308), 2009. Date of Publication: July 2009.

Publisher

Informa Healthcare

Abstract

Naltrexone is a theoretically promising alternative to agonist substitution treatment for opioid dependence, but its effectiveness has been severely limited by poor adherence. This study examined, in an independent sample, a previously observed association between moderate cannabis use and improved retention in naltrexone treatment. Opioid dependent patients (N = 63), admitted for inpatient detoxification and induction onto oral naltrexone, and randomized into a six-month trial of intensive behavioral therapy (Behavioral Naltrexone Therapy) versus a control behavioral therapy (Compliance Enhancement), were classified into three levels of cannabis use during treatment based on biweekly urine toxicology: abstinent (0% cannabis positive urine samples); intermittent use (1% to 79% cannabis positive samples); and consistent use (80% or greater cannabis positive samples). Intermittent cannabis users showed superior retention in naltrexone treatment (median days retained = 133; mean = 112.8, SE = 17.5), compared to abstinent (median = 35; mean = 47.3, SE = 9.2) or consistent users (median = 35; mean = 68.3, SE = 14.1) (log rank = 12.2, df = 2, p =.002). The effect remained significant in a Cox model after adjustment for baseline level of heroin use and during treatment level of cocaine use. Intermittent cannabis use was also associated with greater adherence to naltrexone pill-taking. Treatment interacted with cannabis use level, such that intensive behavioral therapy appeared to moderate the adverse prognosis in the consistent cannabis use group. The association between moderate cannabis use and improved retention on naltrexone treatment was replicated. Experimental studies are needed to directly test the hypothesis that cannabinoid agonists exert a beneficial pharmacological effect on naltrexone maintenance and to understand the mechanism.

ISSN 1055-0496

Publication Type Journal: Article

Journal Name American Journal on Addictions

Volume 18

Issue Part 4

Page 301-308

Year of Publication 2009

Date of Publication July 2009

OPIOIDS / VIROLOGY 2009 <455>

Database EMBASE

Accession Number 2009384628

Authors Meade C.S. McDonald L.J. Weiss R.D.

Institution

(Meade, McDonald, Weiss) McLean Hospital, Harvard Medical School, Belmont, MA,

(Meade) Duke Global Health Institute, 111 Trent Hall, Box 90519, Trent Drive, Durham, NC 27708,

Country of Publication

United Kingdom

Title

HIV risk behavior in opioid dependent adults seeking detoxification treatment: An exploratory comparison of heroin and oxycodone users.

Source

American Journal on Addictions. 18(4)(pp 289-293), 2009. Date of Publication: July 2009.

Publisher

Informa Healthcare

Abstract

Heroin users are at high risk for HIV infection, but little is known about HIV risk in oxycodone users. This study examined HIV risk behaviors in heroin (n = 27) and oxycodone (n = 23) users seeking inpatient detoxification at a private psychiatric hospital. Drug use histories were similar, except oxycodone users used marijuana more frequently. Injection drug risk occurred exclusively among heroin users. The rates of sexual activity (66%), unprotected intercourse (69%), sex while intoxicated (74%), and sex with strangers (24%) were similar, but more oxycodone users had multiple partners (39% vs. 6%, p .05). HIV prevention efforts should target both heroin and oxycodone users.

ISSN 1055-0496

Publication Type Journal: Article

Journal Name American Journal on Addictions

Volume 18

Issue Part 4

Page 289-293

Year of Publication 2009

Date of Publication July 2009

OPIOIDS 2009 <457>

Database EMBASE

Accession Number 2009384623

Authors Chun J. Haug N.A. Guydish J.R. Sorensen J.L. Delucchi K.

Institution

(Chun) Graduate School of Social Welfare, Ewha Womans University, 11-1 Daehyun-Dong, Seodaemun-Gu, Seoul, 120-750, South Korea.

(Haug, Sorensen, Delucchi) Department of Psychiatry, University of California, San Francisco, San Francisco, CA,

(Haug, Sorensen) San Francisco General Hospital, San Francisco, CA,

(Guydish) Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA,

Country of Publication

United Kingdom

Title

Cigarette smoking among opioid-dependent clients in a therapeutic community.

Source

American Journal on Addictions. 18(4)(pp 316-320), 2009. Date of Publication: July 2009.

Publisher

Informa Healthcare

Abstract

This study examines smoking behavior in a sample of 231 opioid-dependent clients entering therapeutic community treatment, and investigates the relationship between smoking behavior and drug treatment outcomes. We applied regression analyses for selected Addiction Severity Index composites (alcohol, drug, medical, psychiatric), including factors for smoking (number of cigarettes per day, expired-air carbon monoxide level, nicotine dependence), time (baseline, 6 and 12-month), and smoking-by-time interaction. This study confirmed a high smoking prevalence (95%) among opioid users. Among participants interviewed at all time points (n = 206), 13% shifted from smoking to non-smoking status at some time after admission. Participants who reported a greater number of cigarettes were more likely to report higher drug severity at any time point.

ISSN 1055-0496

Publication Type Journal: Article

Journal Name American Journal on Addictions

Volume 18

Issue Part 4

Page 316-320

Year of Publication 2009

Date of Publication July 2009

OPIOIDS 2009 <458>

Database EMBASE

Accession Number 2009381251

Authors Dietis N. Guerrini R. Calo G. Salvadori S. Rowbotham D.J. Lambert D.G.

Institution

(Dietis, Lambert) Department of Cardiovascular Sciences, Pharmacology and Therapeutics Group, Division of Anaesthesia, Critical Care and Pain Management, Leicester LE1 5WW, United Kingdom.

(Rowbotham) Department of Health Sciences, Division of Anaesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 5WW, United Kingdom.

(Guerrini, Salvadori) Department of Pharmaceutical Sciences, Section of Pharmacology, University of Ferrara, 44100 Ferrara, Italy.

(Calo) Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, 44100 Ferrara, Italy.

Country of Publication

United Kingdom

Title

Simultaneous targeting of multiple opioid receptors: A strategy to improve side-effect profile.

Source

British Journal of Anaesthesia. 103(1)(pp 38-49), 2009. Date of Publication: July 2009.

Publisher

Oxford University Press

Abstract

Opioid receptors are currently classified as (mu: mOP), delta (delta: dOP), kappa (kappa: kOP) with a fourth related non-classical opioid receptor for nociceptin/orphainin FQ, NOP. Morphine is the current gold standard analgesic acting at MOP receptors but produces a range of variably troublesome side-effects, in particular tolerance. There is now good laboratory evidence to suggest that blocking DOP while activating MOP produces analgesia (or antinociception) without the development of tolerance. Simultaneous targeting of MOP and DOP can be accomplished by: (i) co-administering two selective drugs, (ii) administering one non-selective drug, or (iii) designing a single drug that specifically targets both receptors; a bivalent ligand. Bivalent ligands generally contain two active centres or pharmacophores that are variably separated by a chemical spacer and there are several interesting examples in the literature. For example linking the MOP agonist oxymorphone to the DOP antagonist naltrindole produces a MOP/DOP bivalent ligand that should produce analgesia with reduced tolerance. The type of response/selectivity produced depends on the pharmacophore combination (e.g. oxymorphone and naltrindole as above) and the space between them. Production and evaluation of bivalent ligands is an emerging field in drug design and for anaesthesia, analgesics that are designed not to be highly selective morphine-like (MOP) ligands represents a new avenue for the production of useful drugs for chronic (and in particular cancer) pain.

ISSN 0007-0912

Publication Type Journal: Review

Journal Name British Journal of Anaesthesia

Volume 103

Issue Part 1

Page 38-49

Year of Publication 2009

Date of Publication July 2009

OPIOIDS (A) 2009 <460>

Database EMBASE

Accession Number 2009382988

Authors Coppa-Hopman R.D. Galle J. Pimkine D.

Institution

(Coppa-Hopman, Galle, Pimkine) Department of Psychology, Neuroscience, and Behaviour, McMaster University, Hamilton, ON, Canada.

(Coppa-Hopman) Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T 1R8, Canada.

Country of Publication

United Kingdom

Title

D1 receptor antagonist-induced long-term depression in the medial prefrontal cortex of rat, in vivo: An animal model of psychiatric hypofrontality.

Source

Journal of Psychopharmacology. 23(6)(pp 672-685), 2009. Date of Publication: August 2009.

Publisher

SAGE Publications Ltd

Abstract

The objective of the following experiment was to induce a pathogenic hypofrontal condition by administering a dopamine-1 receptor (D1R) antagonist to rats. The pathophysiological effect of this manipulation upon glutamate-based long-term potentiation (LTP) in the medial prefrontal cortex (mPFC) was examined in vivo. Subjects were surgically implanted with stimulating electrodes into the corpus callosum and recording electrodes into the mPFC. High-frequency stimulation (HFS) was combined with the administration of the selective D1R family agonist A68930 hydrochloride (0.4 mg/kg/mL) and the selective D1R family antagonist SKF 83566 (0.15 mg/kg/mL). The administration of SKF 83566 hydrobromide prevented mPFC LTP, and resulted in HFS-induced long-term depression. This indicates that D1R activation is necessary for the induction of mPFC glutamate-based LTP. This is supported by our finding that the administration of A68930 hydrochloride combined with HFS induced LTP comparable with saline control levels, suggesting that D 1R activation is necessary for the induction of baseline levels of mPFC LTP. Given that the mPFC governs executive behaviours that are subserved by LTP, such as working memory, these findings are relevant for the study of psychopathological conditions in which hypodopaminergic conditions exist in the mPFC and are correlated with psychiatric symptomotology, such as drug addiction and schizophrenia. copyright 2009 British Association for Psychopharmacology.

ISSN 0269-8811

Publication Type Journal: Article

Journal Name Journal of Psychopharmacology

Volume 23

Issue Part 6

Page 672-685

Year of Publication 2009

Date of Publication August 2009

OPIOIDS 2009 <465>

Database EMBASE

Accession Number 2009376550

Authors Lin H. Higgins P. Loh H.H. Law P.-Y. Liao D.

Institution

(Lin, Higgins, Liao) Department of Neuroscience, University of Minnesota, 321 Church St S.E., Minneapolis, MN, United States.

(Lin) Department of Neurology, Chengdu General Military Hospital, Chengdu City, China.

(Loh, Law) Department of Pharmacology, University of Minnesota, 321 Church St S.E., Minneapolis, MN, United States.

(Liao) Department of Neuroscience, University of Minnesota, 321 Church St S.E., Minneapolis, MN 55455, United States.

Country of Publication

United Kingdom

Title

Bidirectional Effects of Fentanyl on Dendritic Spines and AMPA Receptors Depend Upon the Internalization of Mu Opioid Receptors.

Source

Neuropsychopharmacology. 34(9)(pp 2097-2111), 2009. Date of Publication: August 2009.

Publisher

Nature Publishing Group

Abstract

Fentanyl is a frequently used and abused opioid analgesic and can cause internalization of mu opioid receptors (MORs). Receptor internalization modulates the signaling pathways of opioid receptors. As changes in dendritic spines and synaptic AMPA receptors play important roles in addiction and memory loss, we investigated how fentanyl affects dendritic spines and synaptic AMPA receptors in cultured hippocampal neurons. Fentanyl at low concentrations (0.01 and 0.1 M) caused the collapse of dendritic spines and decreased the number of AMPA receptor clusters. In contrast, fentanyl at high concentrations (1 and 10 M) had opposite effects, inducing the emergence of new spines and increasing the number of AMPA receptor clusters. These dose-dependent bidirectional effects of fentanyl were blocked by a selective MOR antagonist CTOP at 5 M. In neurons that had been transfected with HA-tagged or GFP-tagged MORs, fentanyl at high concentrations induced persistent and robust internalization of MORs, whereas fentanyl at lower concentrations induced little or transient receptor internalization. The blockade of receptor internalization with the expression of dominant-negative Dynamin I (the K44E mutant) reversed the effect of fentanyl at high concentrations, supporting a role of receptor internalization in modulating the dose-dependent effects of fentanyl. In contrast to morphine, the effects of fentanyl on dendritic spines are distinctively bidirectional and concentration dependent, probably due to its ability to induce robust internalization of MORs at high concentrations. The characterization of the effects of fentanyl on spines and AMPA receptors may help us understand the roles of MOR internalization in addiction and cognitive deficits. copyright 2009 Nature Publishing Group All rights reserved.

ISSN 0893-133X

Publication Type Journal: Article

Journal Name Neuropsychopharmacology

Volume 34

Issue Part 9

Page 2097-2111

Year of Publication 2009

Date of Publication August 2009

OPIOIDS 2009 <467>

Database EMBASE

Accession Number 2009379377

Authors Wakhlu S.

Institution

(Wakhlu) Psychiatry, UT Southwestern Medical Center, Dallas, TX, United States.

Country of Publication

United Kingdom

Title

Buprenorphine: A review.

Source

Journal of Opioid Management. 5(1)(pp 59-64), 2009. Date of Publication: January-February 2009.

Publisher

Weston Medical Publishing

Abstract

A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000), 1 signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of their practice. Two years later, on October 8, 2002, Suboxone (Buprenorphine/Naloxone) and Subutex (Buprenorphine) received FDA approval for the treatment of opioid addiction. Prior to DATA 2000, opioid maintenance treatment was available through highly regulated methadone clinics. This article discusses opioid addiction in the United States today and the principles of buprenorphine therapy.

ISSN 1551-7489

Publication Type Journal: Review

Journal Name Journal of Opioid Management

Volume 5

Issue Part 1

Page 59-64

Year of Publication 2009

Date of Publication January-February 2009

OPIOIDS 2009 <469>

Database EMBASE

Accession Number 2009384560

Authors Becker W.C. Meghani S.H. Barth K.S. Wiedemer N. Gallagher R.M.

Institution

(Becker, Wiedemer, Gallagher) Philadelphia Veterans Affairs Medical Center, VISN4 MIRECC, Philadelphia, PA,

(Meghani) NewCourtland Center for Transitions and Health, University of Pennsylvania, School of Nursing, Philadelphia, PA,

(Barth) University of Pennsylvania, School of Medicine, Philadelphia, PA,